Your browser doesn't support javascript.
loading
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser, Martin; Beksaç, Meral; Gulbrandsen, Nina; Schjesvold, Fredrik; Hájek, Roman; Moreau, Philippe; de la Fuente, Felipe de Arriba; Mateos, María-Victoria; West, Sharon; Spencer, Andrew; Rajkumar, S Vincent; Suryanarayan, Kaveri; Czorniak, Michael; Li, Cong; Teng, Zhaoyang; Labotka, Richard; Dimopoulos, Meletios A.
Afiliación
  • Kaiser M; Department of Haematology, The Royal Marsden Hospital, London, UK. Martin.Kaiser@icr.ac.uk.
  • Beksaç M; Division of Molecular Pathology, The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, 123 Old Brompton Road, London, SW7 3RP, UK. Martin.Kaiser@icr.ac.uk.
  • Gulbrandsen N; Department of Hematology, Ankara University, Ankara, Turkey.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Hájek R; Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Moreau P; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • de la Fuente FA; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
  • Mateos MV; Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
  • West S; Department of Hematology, University Hospital of Salamanca, CIC, IBM CC, Salamanca, Spain.
  • Spencer A; Department of Haematology, The Royal Marsden Hospital, London, UK.
  • Rajkumar SV; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia.
  • Suryanarayan K; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Czorniak M; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Li C; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Teng Z; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Labotka R; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Dimopoulos MA; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Ann Hematol ; 100(1): 297-302, 2021 Jan.
Article en En | MEDLINE | ID: mdl-33106909
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Alemania